OBJECTIVE: To examine whether cytokine concentrations change in the pulmonary compartment during the development of ventilator-associated pneumonia (VAP). DESIGN: Non-directed bronchial lavage (NBL) was performed every 48 h in critically ill mechanically ventilated patients. Serial measurements of the cytokines tumor necrosis factor (TNF) alpha, interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-10 and the cytokine inhibitors soluble TNFalpha receptor type I (sTNFalphaRI), IL-1 receptor antagonist (IL-1Ra) and soluble IL-1 receptor II (sIL-1RII) were performed on the NBL fluid and matching plasma samples by ELISA. SETTING: An adult medical and surgical university hospital intensive care unit. PATIENTS: Nine patients who developed VAP and nineteen patients who did not develop VAP served as controls. INTERVENTIONS: None. RESULTS: Plasma concentrations of the measured cytokines and cytokine inhibitors did not change significantly in any patients. In control patients, NBL fluid concentrations of sIL-1RII decreased significantly over time (P=0.01). In patients who developed VAP, NBL fluid concentrations of TNFalpha, sTNFalphaRI, IL-1alpha, and IL-1beta increased significantly (P=0.002, P=0.03, P=0.04 and P=0.02, respectively). Furthermore, NBL fluid/plasma concentration ratios for TNFalpha, sTNFalphaRI, IL-1alpha, IL-1Ra and IL-6 increased significantly as VAP developed (P=0.001, P=0.001, P=0.04, P=0.03, and P=0.04, respectively). CONCLUSION: Our results suggest that the production of important cytokines and cytokine inhibitors is compartmentalised within the lung in critically ill mechanically ventilated patients who develop VAP.
OBJECTIVE: To examine whether cytokine concentrations change in the pulmonary compartment during the development of ventilator-associated pneumonia (VAP). DESIGN: Non-directed bronchial lavage (NBL) was performed every 48 h in critically ill mechanically ventilated patients. Serial measurements of the cytokines tumor necrosis factor (TNF) alpha, interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-10 and the cytokine inhibitors soluble TNFalpha receptor type I (sTNFalphaRI), IL-1 receptor antagonist (IL-1Ra) and soluble IL-1 receptor II (sIL-1RII) were performed on the NBL fluid and matching plasma samples by ELISA. SETTING: An adult medical and surgical university hospital intensive care unit. PATIENTS: Nine patients who developed VAP and nineteen patients who did not develop VAP served as controls. INTERVENTIONS: None. RESULTS: Plasma concentrations of the measured cytokines and cytokine inhibitors did not change significantly in any patients. In control patients, NBL fluid concentrations of sIL-1RII decreased significantly over time (P=0.01). In patients who developed VAP, NBL fluid concentrations of TNFalpha, sTNFalphaRI, IL-1alpha, and IL-1beta increased significantly (P=0.002, P=0.03, P=0.04 and P=0.02, respectively). Furthermore, NBL fluid/plasma concentration ratios for TNFalpha, sTNFalphaRI, IL-1alpha, IL-1Ra and IL-6 increased significantly as VAP developed (P=0.001, P=0.001, P=0.04, P=0.03, and P=0.04, respectively). CONCLUSION: Our results suggest that the production of important cytokines and cytokine inhibitors is compartmentalised within the lung in critically ill mechanically ventilated patients who develop VAP.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R LeGall; A Morris; R Spragg Journal: Intensive Care Med Date: 1994 Impact factor: 17.440
Authors: K Kurahashi; O Kajikawa; T Sawa; M Ohara; M A Gropper; D W Frank; T R Martin; J P Wiener-Kronish Journal: J Clin Invest Date: 1999-09 Impact factor: 14.808
Authors: M S Dehoux; A Boutten; J Ostinelli; N Seta; M C Dombret; B Crestani; M Deschenes; J L Trouillet; M Aubier Journal: Am J Respir Crit Care Med Date: 1994-09 Impact factor: 21.405
Authors: A Boutten; M S Dehoux; N Seta; J Ostinelli; P Venembre; B Crestani; M C Dombret; G Durand; M Aubier Journal: Am J Respir Crit Care Med Date: 1996-01 Impact factor: 21.405
Authors: Helena M Linge; Ji Young Lee; Kanta Ochani; Kiyokazu Koga; Nina Kohn; Kaie Ojamaa; Saul R Powell; Edmund J Miller Journal: Exp Lung Res Date: 2015-04-06 Impact factor: 2.459
Authors: D Vuichard; M T Ganter; R C Schimmer; D Suter; C Booy; L Reyes; T Pasch; B Beck-Schimmer Journal: Clin Exp Immunol Date: 2005-08 Impact factor: 4.330
Authors: Rogier M Determann; Julian L Millo; Sébastien Gibot; Johanna C Korevaar; Margreeth B Vroom; Tom van der Poll; Christopher S Garrard; Marcus J Schultz Journal: Intensive Care Med Date: 2005-09-30 Impact factor: 17.440
Authors: Petrus R de Jong; Alvin W L Schadenberg; Nicolaas J G Jansen; Berent J Prakken Journal: Cell Stress Chaperones Date: 2008-07-31 Impact factor: 3.667
Authors: Ali A El-Solh; Mifue Okada; Celestino Pietrantoni; Alan Aquilina; Eileen Berbary Journal: Intensive Care Med Date: 2004-07-23 Impact factor: 17.440
Authors: Pieter R Tuinman; Alexander P Vlaar; Alexander D Cornet; Jorrit J Hofstra; Marcel Levi; Joost C M Meijers; Albertus Beishuizen; Marcus J Schultz; Ab Johan Groeneveld; Nicole P Juffermans Journal: Crit Care Date: 2011-02-11 Impact factor: 9.097
Authors: Rogier M Determann; Julian L Millo; Sam Waddy; Rene Lutter; Chris S Garrard; Marcus J Schultz Journal: BMC Pulm Med Date: 2009-12-03 Impact factor: 3.317
Authors: Rogier M Determann; Annick Royakkers; Esther K Wolthuis; Alexander P Vlaar; Goda Choi; Frederique Paulus; Jorrit-Jan Hofstra; Mart J de Graaff; Johanna C Korevaar; Marcus J Schultz Journal: Crit Care Date: 2010-01-07 Impact factor: 9.097
Authors: Andrew Conway Morris; Kallirroi Kefala; Thomas S Wilkinson; Olga Lucia Moncayo-Nieto; Kevin Dhaliwal; Lesley Farrell; Timothy S Walsh; Simon J Mackenzie; David G Swann; Peter J D Andrews; Niall Anderson; John R W Govan; Ian F Laurenson; Hamish Reid; Donald J Davidson; Christopher Haslett; Jean-Michel Sallenave; A John Simpson Journal: Thorax Date: 2009-10-12 Impact factor: 9.139